Participant Information 
Did you know - Generic copies of Biologic Medicines (such as Adalimumab, Infliximab, Rituximab, Etanercept etc.) are called as Biosimilars.

The aim of this study is to understand the perception of patient/ patient groups towards affordability and availability to biosimilars and how to potentially overcome challenges pertaining to biosimilar treatments. The study is being conducted under the auspices of the University of Hertfordshire in the UK.

What are the possible benefits and risks of participating? 

Participation in this questionnaire is voluntary. There are no known disadvantages or costs whether you participate or not in this study. You may not benefit directly from this study, but the information obtained will make a scientific contribution to the healthcare system of the country. The outcome report from this study will provide benefits to the public and potentially ensure better access to biosimilar medicines.

You and your answers will not be identified, and no one will know whether or not you participated in the study. Once the study is completed, data might be published but no individual information will be disclosed and the information you provide will be treated and kept strictly confidential. 

SurveyMonkey Privacy Policy

Question Title

* 1. Consent to take part
If you have read the participant information above, please click on "Yes" below to indicate your consent for participation.

Question Title

* 2. Which country do you reside in ?

Question Title

* 3. Please specify your gender

Question Title

* 4. What is your age (years) ?

0 of 14 answered
 

T